Laureate Pharma and Selexis SA have entered into a joint-marketing relationship, drawing on their respective strengths in contract manufacturing and cell line development to shorten timelines.
Agilent and Millipore have formed a collaboration to develop fully validated chromatin immunoprecipitation (ChIP) microarray kits that will improve productivity and streamline epigenetic analysis.
Applied Biosystems (ABI) has developed a sequencing-based tool for gene expression analysis that can detect even minute amounts of previously unknown RNA transcripts.
Bayer Healthcare is to deploy a new technique, developed by
Millipore, for genetically engineering cells to produce
pharmaceutically useful proteins that could both increase the yield
and accelerate drug production.
Two new techniques have been developed that could signal the end of
PCR (polymerase chain reaction) amplification for sequencing
applications and dramatically increase the efficiency of sample
preparation.
ZS Genetics has signed up outside academic assistance to speed
up development of its 'revolutionary' microscopy-based genetic
analysis technology platform.
Seattle drug firm ZymoGenetics has taken Bristol-Myers Squibb (BMS)
to court for infringement of its fusion protein technology patents
by several products, including arthritis medication Orencia
(abatacept).
A new laboratory method for distinguishing pathogens from harmless
relatives has been developed by scientists in the US. The
high-throughput technique will enable the quick identification of
pathogens, which could be used for bioterror...
A new easy-to-use laser microdissection system from Olympus is set
to shake up the isolation technology market by reducing sample
handling and contamination when isolating cells for downstream
analysis and making the process routine.
Gentra Systems has introduced its new versaGene DNA Cell
Purification Kit, which responds to the growing need for
high-quality DNA for sensitive downstream applications. The kit
uses chemistry and column design to purify DNA with...
A disposable flask bioreactor designed by Swiss company Integra
Biosciences has been shown to boost cell densities in mammalian
cell culture by a factor of 10 in a study.
US scientists have shown that microRNA (miRNA) plays an essential
role in the development of the fruit fly. The discovery means that
miRNA could emerge as a new target for interventions aimed at
treating disease, or as a therapeutic...
Qiagen has released two protein purification kits that provide
affordable automation as a way to increase throughput and free up
valuable manpower for less routine tasks.
Biosample management firm, GenVault announced an exclusive
agreement to acquire the full rights to a DNA labelling
intellectual property, which allows researchers to identify the
sample through its complete downstream analysis to...
Boehringer Ingelheim Austria has been selected to win a Technology
Leadership award by Frost & Sullivan for its activities in the
contract manufacture of biotherapeutic proteins, and particularly
plasmid DNA.
Canada's SemBioSys Genetics has been granted a US patent on a
vaccine production system that uses genetically modified seeds as
biological factories of vaccine antigens.
Invitrogen, which supplies reagents, services and software for the
life science market, has continued its acquisitive streak with the
announcement that it is paying $35 million (€27.5m) for a UK firm -
DNA Research Innovations - specialising...
Dutch biotech firm Qiagen has announced the acquisition of key
assets of Molecular Staging (MSI), which includes the Whole Genome
Amplification (WGA) technology, designed to eliminate limitations
created by scarce quantities of DNA...
Germany's Icon Genetics has published details of its proprietary
expression technology, designed to improve the production of
biopharmaceuticals and other proteins in genetically-modified
plants.
Researchers in Finland and the US have identified a gene that
predisposes people to one of the most common causes of coronary
heart disease, raising the hope that it could represent a new
target for drug treatment.
Two France-based companies have pooled their resources to set up a
new venture specialising in the contract development and
manufacturing of biologicals drugs.
DSM Biologics has dissolved its relationship with Qiagen and
Valentis regarding the pAlliance, a consortium supplying
ultra-pure, stable DNA plasmids and formulated DNA
Swiss life-science company Lonza announced on Tuesday that it is to
strengthen the production of oligonucleotides - an emerging new
class of therapeutics consisting of short nucleic acid chains
interfering in the processing of genetic...